Backgrounds: Diabetes mellitus (DM)-induced morphological and/or functional complications may alter the pharmacokinetic profiles of mangiferin. This study aims to compare pharmacokinetic profiles of mangiferin in normal and alloxan-induced diabetic rats after oral and intravenous administration. Methods: Mangiferin was administered orally (10 mg/kg) and intravenously (2 mg/kg) to normal and alloxan-induced diabetic Sprague-Dawley (SD) rats (n = 8). Blood samples were collected at different time points post-dose. Mangiferin and esculentoside (internal standard)  were analyzed by Waters Acquity ultra-performance liquid chromatography system and TSQ Quantum Ultra triple quadrupole mass spectrometer (UPLC-MS/MS). Results: Mangiferin in normal and alloxan-induced diabetic rats experienced serious first-pass effect, which resulted in 1.71 and 0.80% of oral bioavailability respectively. Meanwhile, mangiferin was predominantly restricted to blood but not extensively distributed to organ tissues after intravenous administration. Compared with normal rats, the diabetic condition induced 53.26 and 50.90% decreases in Cmax and AUC0–t, respectively, for mangiferin after oral administration, and 63.08% decreases in Cmax after intravenous administration. Conclusions: Compared to normal rats, pharmacokinetic parameters of mangiferin were altered in diabetic condition induced by alloxan. The findings might help to provide useful evidence for modeling of diabetic rats and the clinical applications of mangiferin.

1.
Saha S, Sadhukhan P, Sil PC: Mangiferin: a xanthonoid with multipotent anti-inflammatory potential. Biofactors 2016; 42: 459–474.
2.
Singh SK, Kumar Y, Kumar SS, Sharma VK, Dua K, Samad A: Antimicrobial evaluation of mangiferin analogues. Indian J Pharm Sci 2009; 71: 328–331.
3.
Peng ZG, Yao YB, Yang J, Tang YL, Huang X: Mangiferin induces cell cycle arrest at G2/M phase through ATR-Chk1 pathway in HL-60 leukemia cells. Genet Mol Res 2015; 14: 4989–5002.
4.
Guo HW, Yun CX, Hou GH, Du J, Huang X, Lu Y, Keller ET, Zhang J, Deng JG: Mangiferin attenuates Th1/Th2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. PLoS One 2014; 9:e100394.
5.
Wang RR, Gao YD, Ma CH, Zhang XJ, Huang CG, Huang JF, Zheng YT: Mangiferin, an anti-HIV-1 agent targeting protease and effective against resistant strains. Molecules 2011; 16: 4264–4277.
6.
Campos-Esparza MR, Sánchez-Gómez MV, Matute C: Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009; 45: 358–368.
7.
Na L, Zhang Q, Jiang S, Du S, Zhang W, Li Y, Sun C, Niu Y: Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial. Sci Rep 2015; 5: 10344.
8.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27(suppl 1):S5–S10.
9.
Gunnlaugsdottir E, Halldorsdottir S, Klein R, Eiriksdottir G, Klein BE, Benediktsson R, Harris TB, Launer LJ, Aspelund T, Gudnason V, Cotch MF, Jonasson F: Retinopathy in old persons with and without diabetes mellitus: the Age, Gene/Environment Susceptibility-Reykjavik Study (AGES-R). Diabetologia 2012; 55: 671–680.
10.
Frokjaer JB, Andersen SD, Ejskjaer N, Funch-Jensen P, Drewes AM, Gregersen H: Impaired contractility and remodeling of the upper gastrointestinal tract in diabetes mellitus type-1. World J Gastroenterol. 2007; 13: 4881–4890.
11.
Han C, Rice MW, Cai D: Neuroinflammatory and autonomic mechanisms in diabetes and hypertension. Am J Physiol Endocrinol Metab 2016; 311:E32–E41.
12.
Xing R, He X, Liu S, Yu H, Qin Y, Chen X, Li K, Li R, Li P: Antidiabetic activity of differently regioselective chitosan sulfates in alloxan-induced diabetic rats. Mar Drugs 2015; 13: 3072–3090.
13.
Liu H, Wu B, Pan G, He L, Li Z, Fan M, Jian L, Chen M, Wang K, Huang C: Metabolism and pharmacokinetics of mangiferin in conventional rats, pseudo-germ-free rats, and streptozotocin-induced diabetic rats. Drug Metab Dispos 2012; 40: 2109–2118.
14.
Pal PB, Sinha K, Sil PC: Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNFα related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One 2014; 9:e107220.
15.
van Waarde WM, Verkade HJ, Wolters H, Havinga R, Baller J, Bloks V, Müller M, Sauer PJ, Kuipers F: Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 2002; 122: 1842–1852.
16.
Danilova IG, Sarapultsev PA, Medvedeva SU, Gette IF, Bulavintceva TS, Sarapultsev AP: Morphological restructuring of myocardium during the early phase of experimental diabetes mellitus. Anat Rec (Hoboken) 2015; 298: 396–407.
17.
Ichiki H, Miura T, Kubo M, Ishihara E, Komatsu Y, Tanigawa K, Okada M: New antidiabetic compounds, mangiferin and its glucoside. Biol Pharm Bull 1998; 21: 1389–1390.
18.
Huang TH, Peng G, Li GQ, Yamahara J, Roufogalis BD, Li Y: Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. Toxicol Appl Pharmacol 2006; 210: 225–235.
19.
Kammalla AK, Ramasamy MK, Inampudi J, Dubey GP, Agrawal A, Kaliappan I: Comparative pharmacokinetic study of mangiferin after oral administration of pure mangiferin and US patented polyherbal formulation to rats. AAPS PharmSciTech 2015; 16: 250–258.
20.
Hou Y, Fan S, Zhang H, Gu Y, Yu X, Li B: Pharmacokinetic study of mangiferin in rat plasma and retina using high-performance liquid chromatography. Mol Vis 2010; 16: 1659–1668.
21.
Liu Y, Xu F, Zeng X, Yang L, Deng Y, Wu Z, Feng Y, and Li X: Application of a liquid chromatography/tandem mass spectrometry method to pharmacokinetic study of mangiferin in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 3345–3350.
22.
Han D, Chen C, Zhang C, Zhang Y, Tang X: Determination of mangiferin in rat plasma by liquid-liquid extraction with UPLC-MS/MS. J Pharm Biomed Anal. 2010; 51: 260–263.
23.
Federiuk IF, Casey HM, Quinn MJ, Wood MD, Ward WK. Induction of type-1 diabetes mellitus in laboratory rats by use of alloxan: route of administration, pitfalls, and insulin treatment. Comp Med 2004; 54: 252–257.
24.
Dai XS, Kang J, Wan RH, Rong YL, Wang T: Establishment of type I diabetes mellitus animal model induced by alloxan. J Reg Anat Oper Surg 2011; 120: 20–21.
25.
International Conference on Harmonization (Q2R1): Validation of Analytical Procedures: Text and Methodology. Geneva, 1996.
26.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3–26.
27.
Liu H, Wang K, Tang Y, Sun Z, Jian L, Li Z, Wu B, Huang C: Structure elucidation of in vivo and in vitro metabolites of mangiferin. J Pharm Biomed Anal. 2011; 55: 1075–1082.
28.
Kim YC: Pharmacokinetic changes of drugs in rats with diabetes mellitus with respect to CYP isozymes changes. Ph.D. thesis. Seoul National University, Seoul, 2005.
29.
Yamazoe Y, Murayama N, Shimada M, Yamauchi K, Kato R: Cytochrome P450 in livers of diabetic rats: regulation by growth hormone and insulin. Arch Biochem Biophys 1989; 268: 567–575.
30.
Raza H, Ahmed I, Lakhani MS, Sharma AK, Pallot D, Montague W: Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem Pharmacol 1996; 52: 1639–1642.
31.
Chieli E, Romiti N, Rodeiro I, and Garrido G: In vitro modulation of ABCB1/Pglycoprotein expression by polyphenols from Mangifera indica. Chem Biol Interact 2010; 186: 287–294.
32.
Yu S, Yu Y, Liu L, Wang X, Lu S, Liang Y, Liu X, Xie L, Wang G: Increased plasma exposures of five protoberberine alkaloids from Coptidis Rhizoma in streptozotocin-induced diabetic rats: is P-GP involved? Planta Med 2010; 76: 876–881.
33.
Tramonti G, Xie P, Wallner EI, Danesh FR, Kanwar YS: Expression and functional characteristic of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J Physiol Renal Physiol 2006; 291: 972–980.
34.
Horie M, Miura T, Hirakata S, Hosoyama A, Sugino S, Umeno A, Murotomi K, Yoshida Y, Koike T: Comparative analysis of the intestinal flora in type 2 diabetes and nondiabetic mice. Exp Anim 2017; 66: 405–416.
35.
Carnovale CE, Marinelli RA, Rodriguez garay EA: bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol1986; 35: 2625–2628.
36.
Price, VF, Jollow DJ: Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity. Biochem Pharmacol 1986; 35: 687–695.
37.
Kim SH, Kim WB, Lee MG: Pharmacokinetics of a new carbapenem, DA-1131, after inravenous administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos 1998; 19: 303–308.
38.
Junshik C, Byungchul C: Pharmacokinetic changes of oral sulfamethoxazole in rabbits with diabetes mellitus induced by alloxan. Res Commun Mol Pathol Pharmacol. 2000; 108(5–6): 332–340.
39.
Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–1095.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.